B.L. Clarke, E.M. Brown, M.T. Collins, H. Jüppner, P. Lakatos, M.A. Levine, M.M. Mannstadt, J.P. Bilezikian, A.F. Romanischen, R.V. Thakker, Epidemiology and diagnosis of hypoparathyroidism. J. Clin. Endocrinol. Metab. 101, 2284–2299 (2016). https://doi.org/10.1210/jc.2015-3908

Article  PubMed  PubMed Central  CAS  Google Scholar 

G. Tuli, R. Buganza, D. Tessaris, S. Einaudi, P. Matarazzo, L. de Sanctis, Teriparatide (rhPTH 1–34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism. Endocrine 67, 457–465 (2020). https://doi.org/10.1007/s12020-019-02128-z

Article  PubMed  CAS  Google Scholar 

J.P. Bilezikian, Hypoparathyroidism. J. Clin. Endocrinol. Metab. 105, 1722–1736 (2020). https://doi.org/10.1210/clinem/dgaa113

Article  PubMed  PubMed Central  Google Scholar 

M. Mannstadt, L. Cianferotti, R.I. Gafni, F. Giusti, E.H. Kemp, C.A. Koch, K.L. Roszko, L. Yao, G.H. Guyatt, R.V. Yhakker, W. Xia, M.L. Brandi, Hypoparathyroidism: genetics and diagnosis. J. Bone Min. Res. 37, 2615–2629 (2022). https://doi.org/10.1002/jbmr.4667

Article  CAS  Google Scholar 

R.I. Gafni, M.T. Collins, Hypoparathyroidism. N. Engl. J. Med. 380, 1738–1747 (2019). https://doi.org/10.1056/NEJMcp1800213

Article  PubMed  Google Scholar 

F. Albright, R. Ellsworth, Studies on the physiology of the parathyroid glands: I. Calcium and phosphorus studies on a case of idiopathic hypoparathyroidism. J. Clin. Invest. 7, 183–201 (1929)

Article  PubMed  PubMed Central  CAS  Google Scholar 

K.K. Winer, J.A. Yanovski, G.B. Cutler Jr., Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hyoparathyroidism. JAMA 276, 631–636 (1996)

Article  PubMed  CAS  Google Scholar 

G. Marcucci, G. Beccuti, I.G. Caros, F. Cetani, L. Cianferotti, A.M. Colao, C. Di Somma, M. Duradoni, A. Elefante, L. Ghizzoni, M. Giusti, A.G. Lania, E. Lavezzi, B. Madeo, G. Mantovani, C. Marcocci, L. Masi, S. Parri, F. Pigliaru, A. Santonati, A. Spada, L. Vera, M.L. Brandi, Multicenter retro‐prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment. J. Endocrinol. Invest. 45, 1653–1662 (2022). https://doi.org/10.1007/s40618-022-01800-y

Article  PubMed  PubMed Central  CAS  Google Scholar 

E. Laurer, J. Grünberger, U. Naidoo, R. Lanzersdorfer, M. Wilmleitner, K. Tischlinger, W. Högler, Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism. Bone 144, 115834 (2021). https://doi.org/10.1016/j.bone.2020.115834

Article  PubMed  CAS  Google Scholar 

https://www.aifa.gov.it/en/-/nota-informativa-importante-su-natpar-ormone-paratiroideo-1

G. Tabacco, J.P. Bilezikian, New directions in treatment of hypoparathyroidism. Endocrinol. Metab. Clin. North Am. 47, 901–915 (2018). https://doi.org/10.1016/j.ecl.2018.07.013

Article  PubMed  Google Scholar 

A. Linglart, A. Rothenbuhler, I. Gueorgieva, P. Lucchini, C. Silve, P. Bougnères, Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism. J. Clin. Endocrinol. Metab. 96, 3308–3312 (2011). https://doi.org/10.1210/jc.2011-1359

Article  PubMed  CAS  Google Scholar 

K.K. Winer, B. Zhang, J.A. Shrader, D. Peterson, M. Smith, P.S. Albert, G.B. Cutler Jr., Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J. Clin. Endocrinol. Metab 97, 391–399 (2012). https://doi.org/10.1210/jc.2011-1908

Article  PubMed  CAS  Google Scholar 

K.K. Winer, N. Sinaii, J. Reynolds, D. Peterson, K. Dowdy, G.B. Cutler Jr., Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 95, 2680–2688 (2010). https://doi.org/10.1210/jc.2009-2464

Article  PubMed  PubMed Central  CAS  Google Scholar 

J.L. Vahle, M. Sato, G.G. Long, J.K. Young, P.C. Francis, J.A. Engelhardt, M.S. Westmore, Y. Linda, J.B. Nold, Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 30, 312–321 (2002). https://doi.org/10.1080/01926230252929882

Article  PubMed  CAS  Google Scholar 

A. Khan, L. Rejnmark, M. Rubin, P. Schwarz, T. Vokes, B. Clarke, I. Ahmed, L. Hofbauer, C. Marcocci, U. Pagotto, A. Palermo, E. Eriksen, M. Brod, D. Markova, A. Smith, S. Pihl, S. Mourya, D.B. Karpf, A.D. Shu, PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. J. Clin. Endocrinol. Metab. 107, e372–e385 (2022). https://doi.org/10.1210/clinem/dgab577

Article  PubMed  Google Scholar 

https://www.ema.europa.eu/en/medicines/human/EPAR/yorvipath#:~:text=Other%20information%20about%20Yorvipath,EU%20on%2017%20November%202023

https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-announces-extension-us-food-and-drug-1

L. Holten-Andersen, S. Pihl, C.E. Rasmussen, J. Zettler, G. Maitro, J. Baron, S. Heinig, E. Hoffmann, T. Wegge, M. Krusch, F. Faltinger, S. Kilian, K. Sprogoe, D.B. Karpf, V.M. Breinholt, F. Cleemann, Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism. J. Bone Miner. Res. 34, 2075–2086 (2019). https://doi.org/10.1002/jbmr.3824

Article  PubMed  CAS  Google Scholar 

I. Ahmed, E. Eriksen, R.L. Hofbaue, A. Khan, J. Le, C. Marcocci, D. Markova, U. Pagotto, A. Palermo, S. Pihl, L. Rjnmark, P. Schwarz, A. Shu, C. Sibley, S. Vansaghi, T. Vokes, B. Clarke, OR21-1 The PaTH forward trial: efficacy and safety of TransCon PTH through week 84 for adults with hypoparathyroidism. J. Endocr. Soc. 6(Supplement 1), A193 (2022). https://doi.org/10.1210/jendso/bvac150.398

Article  PubMed Central  Google Scholar 

A.A. Khan, M.R. Rubin, P. Schwarz, T. Vokes, D.M. Shoback, C. Gagnon, A. Palermo, C. Marcocci, B.L. Clarke, L.G. Abbott, L.C. Hofbauer, L. Kohlmeier, S. Pihl, X. An, W.F. Eng, A.R. Smith, J. Ukena, C.T. Sibley, A.D. Shu, L. Rejnmark, Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the Phase 3 PaTHway Trial. J. Bone Miner. Res. 38, 14–25 (2023). https://doi.org/10.1002/jbmr.4726

Article  PubMed  CAS  Google Scholar 

L. Rejnmark, E.O. Gosmanova, A.A. Khan, N. Makita, Y. Imanishi, Y. Takeuchi, S. Sprague, D.M. Shoback, L. Kohlmeier, M.R. Rubin, A. Palermo, P. Schwarz, C. Gagnon, E. Tsourdi, C. Zhao, M.A. Makara, M.S. Ominsky, B. Lai, J. Ukena, C.T. Sibley, A.D. Shu, Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 PaTHway Trial. Adv Ther 41, 2500–2518 (2024). https://doi.org/10.1007/s12325-024-02843-8

Article  PubMed  PubMed Central  CAS  Google Scholar 

J. Guo, A. Khatri, A. Maeda, J.T. Potts Jr, H. Jüppner, T.J. Gardella, Prolonged pharmacokinetic and pharmacodynamic actions of a pegylated parathyroid hormone (1-34) peptide fragment. J. Bone Miner. Res. 32, 86–98 (2017). https://doi.org/10.1002/jbmr.2917

Article  PubMed  CAS  Google Scholar 

S. Allas, M. Ovize, M.D. Culler, C. Geraul, J. van de Wetering, M. Mannstadt, A single administration of AZP-3601, a Novel, Long-Acting PTH analog, induces a significant and sustained calcemic response: preliminary data from a randomized, double-blind, placebo-controlled phase 1 study. J. Endocr. Soc. 5(Supplement 1), A254 (2021). https://doi.org/10.1210/jendso/bvab048.516

Article  PubMed Central  Google Scholar 

M. Shimizu, E. Joyashiki, H. Noda, T. Watanabe, M. Okazaki, M. Nagayasu, K. Adachi, T. Tamura, J.T. Potts Jr., T.J. Gardella, Y. Kawabe, Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys. J. Bone Miner. Res. 31, 1405–1412 (2016). https://doi.org/10.1002/jbmr.2811

Article  PubMed  CAS  Google Scholar 

R. Bi, Y. Fan, K. Lauter, J. Hu, T. Watanabe, J. Cradock, N.Q. Yua, T. Gardella, M. Mannstadt, Diphtheria toxin- and GFP-based mouse models of acquired hypoparathyroidism and treatment with a long-acting parathyroid hormone analog. J. Bone Miner. Res. 31, 975–984 (2016). https://doi.org/10.1002/jbmr.2769

Article  PubMed  CAS  Google Scholar 

M. Culler, T. Gardella, C. Aksu, AZP-3601, a Long-Acting Parathyroid Hormone (PTH) Analog, Normalizes Blood Calcium in Thyroparathyroidectomized (TPTX) rats without causing deleterious changes in bone. J. Endocr. Soc. 6(Supplement 1), A196 (2022). https://doi.org/10.1210/jendso/bvac150.403

Article  PubMed Central  Google Scholar 

P. Kamenicky, I. Takacs, E. Mezosi, A. Soto, L. Figueres, S. Lemoine, F. Borson-Chazot, I. Capel, M.A. Angeles Artazcoz Galvez Moreno, M. Ovize, T. OuldRouis, S. Allas, M. Sumeray, M. Mannstadt, OR23-04 treatment of chronic hypoparathyroidism with eneboparatide (AZP-3601), a novel PTH 1 receptor agonist: results from a phase 2 trial. J. Endocr. Soc. 7(Suppl 1), bvad114.562 (2023). https://doi.org/10.1210/jendso/bvad114.562

Article  PubMed Central